CHICAGO--(BUSINESS WIRE)--The global pharmaceutical industry experienced a return to revenue growth despite high-profile patent expirations and other ongoing challenges, according to Fitch Ratings.
Drug manufacturers in Fitch's portfolio saw an average weighted revenue increase of 2.1% in Q3 2011, adjusting for currency changes and consolidation activity within the past 12 months. This increase came despite pressure from generic competition and government cost containment.
Drug manufacturers in Fitch's portfolio saw an average weighted revenue increase of 2.1% in Q3 2011, adjusting for currency changes and consolidation activity within the past 12 months. This increase came despite pressure from generic competition and government cost containment.
